Need Noxafil (Posaconazole)
Copay Assistance?

Noxafil copay assistance refers to financial support programs—including manufacturer copay cards, patient assistance programs, and nonprofit foundation grants—that help reduce the out-of-pocket cost of Noxafil (posaconazole) for eligible patients. QuickRx Specialty Pharmacy provides free enrollment support to help identify and apply for programs you may qualify for based on your insurance and financial situation. Eligible patients may pay $0 per prescription depending on insurance and program eligibility.

Eligibility for Noxafil copay assistance varies by program. Manufacturer copay card programs are generally available to patients with commercial (private) insurance who are prescribed brand Noxafil. Patient assistance programs are typically available to patients who are uninsured, underinsured, or whose government insurance (such as Medicare or Medicaid) does not cover the copay card benefit. QuickRx patient navigators evaluate your specific situation to identify the programs you are most likely to qualify for.

No. QuickRx Specialty Pharmacy provides copay assistance enrollment support as a completely free service. There are no fees, no hidden charges, and no obligation. Our patient navigator team assists with your Noxafil application because we believe cost should never be a barrier to treatment.

Federal law restricts the use of manufacturer copay cards for patients with Medicare coverage. However, Medicare patients may still qualify for patient assistance programs or nonprofit foundation grants. The 2025 Inflation Reduction Act also capped Medicare Part D out-of-pocket costs at $2,000 per year, which has reduced the financial burden for many patients on specialty medications. QuickRx patient navigators can review your specific coverage and identify options available to you.

You can apply by completing the secure form on this page or by calling our patient navigator team directly at (917) 830-2525. We will verify your insurance coverage, identify applicable assistance programs, coordinate any prior authorization required, and manage all enrollment paperwork on your behalf at no charge.

Yes. QuickRx Specialty Pharmacy dispenses both brand Noxafil and generic posaconazole nationwide. Generic posaconazole is widely available in the United States and is the most commonly dispensed form for adult patients. Whether your prescriber has written for brand Noxafil or the generic version, QuickRx coordinates dispensing, insurance verification, prior authorization, and home delivery to all 50 states. Call (917) 830-2525 to get started.

Yes. Generic posaconazole is commercially available in the United States in multiple formulations, including delayed-release tablets, intravenous solution, and immediate-release oral suspension. Generic posaconazole is therapeutically equivalent to brand Noxafil and is the most commonly dispensed form. QuickRx dispenses both brand and generic posaconazole. Your prescriber will determine which formulation is right for your specific situation.

Noxafil (posaconazole) is FDA-approved to treat invasive aspergillosis in adults and pediatric patients 2 years and older, oropharyngeal candidiasis in adults and pediatric patients 13 years and older (including patients refractory to itraconazole or fluconazole), and to prevent invasive Aspergillus and Candida infections in severely immunocompromised patients—including those receiving hematopoietic stem cell transplants with graft-versus-host disease, or patients with hematologic malignancies and prolonged neutropenia due to chemotherapy. Posaconazole works by interfering with fungal cell membrane formation, inhibiting fungal growth.

Noxafil (posaconazole) is available in four formulations that are NOT interchangeable due to dosing differences:

• Delayed-release tablets (100 mg): The most commonly prescribed form for adults and pediatric patients weighing more than 40 kg. Preferred over the immediate-release suspension because it is easier to administer, better tolerated, and more reliably absorbed.
• Intravenous (IV) solution (300 mg/16.7 mL): Used in hospitalized patients or those unable to tolerate oral therapy. Administered via central line.
• Delayed-release oral suspension: For pediatric patients 2 years and older weighing 10 to 40 kg. Reconstituted just before administration.
• Immediate-release oral suspension (40 mg/mL): Must be taken with a full meal or acidic carbonated beverage for proper absorption.

Your prescriber will choose the formulation based on your age, weight, diagnosis, and ability to tolerate oral therapy. Always follow your prescribed formulation exactly—do not substitute between forms without your prescriber’s guidance.

How Noxafil is taken depends on the formulation:

• Delayed-release tablets: Swallow whole with water. Take with food when possible, but may be taken with or without food. Do not crush, chew, or divide the tablets.
• Immediate-release oral suspension: Shake well before use. Take during or within 20 minutes of a full meal, an oral liquid nutritional supplement, or an acidic carbonated beverage (such as ginger ale). Food is critical for proper absorption.
• Delayed-release oral suspension (pediatric): Mixed using the provided kit and administered with food within 1 hour of preparation.
• Intravenous solution: Administered by a healthcare professional, typically over 90 minutes via central line.

Follow your prescriber’s instructions exactly. If you have trouble swallowing or eating full meals, contact your prescriber—alternative formulations or antifungal therapies may be appropriate.

Common side effects of Noxafil (posaconazole) reported in clinical trials include nausea (19% to 38%), diarrhea (18% to 42%), vomiting (12% to 29%), fever (21% to 45%), headache (12% to 28%), abdominal pain (10% to 27%), skin rash (15% to 24%), low potassium levels (22% to 30%), constipation (8% to 21%), cough (9% to 24%), and fatigue (8% to 17%). More serious but less common side effects can include liver problems, irregular heart rhythm (QT prolongation), severe allergic reactions, and pseudoaldosteronism (a condition involving elevated blood pressure and electrolyte changes). Patients should report any unusual symptoms to their prescriber promptly. This is not a complete list of side effects.

Posaconazole is a strong inhibitor of the CYP3A4 liver enzyme and can significantly increase blood levels of many medications. Coadministration is contraindicated with:

• Sirolimus
• Ergot alkaloids (such as ergotamine and dihydroergotamine)
• HMG-CoA reductase inhibitors (statins) metabolized through CYP3A4, including atorvastatin, lovastatin, and simvastatin
• CYP3A4 substrates that prolong the QT interval, such as pimozide and quinidine
• Venetoclax during initiation or ramp-up phase in patients with CLL or SLL

Many other medications require dose adjustments when combined with posaconazole, including tacrolimus, cyclosporine, ibrutinib, vincristine, midazolam, and certain HIV medications. Always provide your prescriber and pharmacist with a complete list of every medication, supplement, and over-the-counter product you take.

Posaconazole blood levels can vary significantly between patients, especially for those taking the immediate-release oral suspension. Therapeutic drug monitoring (TDM) involves measuring posaconazole levels in your blood to make sure you are getting enough medication to fight or prevent your fungal infection without reaching toxic levels. Your prescriber may order TDM after you have been on therapy for at least 5 to 7 days, and periodically afterward based on your clinical situation. Other routine monitoring may include liver function tests, electrolyte panels (potassium, magnesium, calcium), complete blood count, and kidney function. QuickRx coordinates with your prescriber to support TDM and other monitoring needs.

Yes. Noxafil is FDA-approved for pediatric patients 2 years and older for the prevention of invasive Aspergillus and Candida infections, and for the treatment of invasive aspergillosis. Pediatric dosing is weight-based and varies by formulation. The delayed-release oral suspension is specifically formulated for pediatric patients ages 2 and older weighing 10 to 40 kg, and the delayed-release tablets are used in pediatric patients weighing more than 40 kg. The immediate-release oral suspension is approved for pediatric patients 13 years and older for oropharyngeal candidiasis. Your child’s prescriber will determine the appropriate formulation and dose.

Yes. QuickRx Specialty Pharmacy is licensed to dispense and ship Noxafil (posaconazole) to patients in all 50 states. We provide free home delivery with appropriate handling and packaging for both oral and refrigerated formulations. Call us at (917) 830-2525 to get started, or fill out the secure form on this page.